Aurinia settles with Teva, helping stave off potential Lupkynis generic until late 2036

Aurinia Pharmaceuticals has settled a patent infringement suit with Teva Pharmaceuticals, keeping Teva's proposed generic of the lupus drug Lupkynis (voclosporin) off the U.S. market until December 2036, unless certain defined contingencies occur earlier. The settlement assumes Teva wins FDA approval of its version. Aurinia still faces patent litigation with DifGen, Dr. Reddy's, Hikma, Sandoz and Zydus in U.S. District Court in New Jersey.